1 completed, 1 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Inotersen: new trials by email Literature Review of Inotersen trials Research Report on Inotersen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients Inotersen - Amyloidosis | Phase 2 | Terminated | Brigham and Women's Hospital | 31 | 2019-02-28 | 2026-02-20 |
| Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy Inotersen, Placebo - FAP, Familial Amyloid Polyneuropathy | Phase 2 / Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 173 | 2013-03-15 | 2019-07-17 |
Amyloidosis (2) · Amyloid Neuropathies, Familial (1)
Brigham and Women's Hospital (1) · Ionis Pharmaceuticals, Inc. (1)
United States (2) · Argentina (1) · Brazil (1) · France (1) · Germany (1) · Italy (1) · New Zealand (1) · Portugal (1) · Spain (1) · United Kingdom (1)
Rodney Falk, MD (1)
PMID 29972757, PMID 30169969, PMID 30219500, PMID 31853709, PMID 32654156, PMID 32654212, PMID 32833564, PMID 34125267, PMID 34355354, PMID 35766224, PMID 35799473, PMID 38065307, PMID 41913562, PMID 41937511